By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
Weight loss drug prices in Israel: why they matter
Weight loss drug prices are one of the topics my patients ask about most. Incretin-based drugs such as Wegovy and Mounjaro have changed the way we treat obesity. However, they also raise hard questions about cost, access and what Israel’s health funds (HMOs) will cover. In 2026, the gap between how well these drugs work and what they cost feels wider than ever. So in this article I have gathered the current prices, the rules for getting a discount, and the prices of the two new pills: Foundayo and the Wegovy pill.
Demand keeps growing. I look at the numbers in my article on how many people use weight loss drugs in Israel and the US.
Weight loss drug prices: Wegovy injections
Wegovy contains semaglutide at doses designed for obesity treatment. In addition, it comes in several dose steps, from 0.25 mg up to the full treatment dose of 2.4 mg. Moreover, each pen holds four weekly injections, so one pen lasts a month. According to the Maccabi drug price list, the consumer price of a pen ranges from 640.24 to 1,070.02 shekels (NIS), depending on the dose. With supplementary insurance the discount is 50%, so you will pay roughly 320 to 535 NIS a month.
Keep in mind that the price is not the same at every step. The starting doses, 0.25 to 1 mg, cost about 640 to 677 NIS. The maintenance doses cost more: 907.26 NIS for 1.7 mg and 1,070.02 NIS for 2.4 mg. As a result, spending rises as treatment goes on. With supplementary insurance, the yearly cost comes to roughly 3,840 to 6,420 NIS.
Weight loss drug prices: Mounjaro
Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP. It is one of the most effective weight loss drugs available today. In the SURMOUNT-5 trial, which compared the two drugs head to head, patients on Mounjaro lost 20.2% of their body weight, compared with 13.7% on Wegovy. On the other hand, that effectiveness also comes with a higher price.
According to the Maccabi price list, the consumer price of a Mounjaro pack ranges from 799.93 NIS for 2.5 mg to 1,987.84 NIS for 12.5 mg. Meanwhile, the 5 mg dose costs 1,056.40 NIS, and the 7.5 and 10 mg doses cost 1,468.64 NIS. With supplementary insurance the discount is usually 50%, which means about 400 to 994 NIS. At Clalit, for example, the co-payment was set in December 2025 at about 442 to 885 NIS a month. In addition, people with type 2 diabetes in this track paid 360 NIS a month at every dose.
Foundayo: a pill instead of an injection
Since September 15, 2026, there has also been a pill option. Foundayo, which contains orforglipron, reached Israeli pharmacies. A pack of 30 tablets lasts a month. The consumer price is 691.59 NIS for the 0.8 and 2.5 mg doses, and 972.08 NIS for the 5.5 and 9 mg doses. For the 14.5 and 17.2 mg doses, the price is 1,146.46 NIS.
The pill is not in the national health basket, and the health funds give no discount on it. Therefore, the price at your health fund is the same as the consumer price. The yearly cost comes to roughly 8,300 to 13,760 NIS. You can read more in my article on the new pill in Israel.
Since these costs add up over months and years, I explain how to plan a long-term weight loss drug budget in a separate guide.
The Wegovy pill: what does it cost?
In November 2026, the Wegovy pill also arrived in Israel. It contains oral semaglutide. For now, it is available through a Form 29G import request. Here too, a pack of 30 tablets lasts a month. The consumer price is 760.74 NIS for the 1.5 and 4 mg doses, 1,069.28 NIS for 9 mg and 1,261.10 NIS for 25 mg.
Like Foundayo, the Wegovy pill does not yet have a health fund discount. As a result, the yearly cost comes to roughly 9,130 to 15,130 NIS. For results, dosing and how to take it, see my article on the Wegovy pill in Israel.
Price table: weight loss drug prices at a glance
The table below lists weight loss drug prices for each dose, at the consumer list price. For the injections, it also shows the estimated price with supplementary insurance, after a 50% discount. For the pills, by contrast, the health fund price is the same as the consumer price.
| Drug and dose | Consumer price (NIS) | With supplementary insurance (NIS) |
|---|---|---|
| Wegovy injection 0.25 mg | 676.69 | 338.35 |
| Wegovy injection 0.5 mg | 640.24 | 320.12 |
| Wegovy injection 1 mg | 645.47 | 322.74 |
| Wegovy injection 1.7 mg | 907.26 | 453.63 |
| Wegovy injection 2.4 mg | 1,070.02 | 535.01 |
| Mounjaro 2.5 mg | 799.93 | 399.97 |
| Mounjaro 5 mg | 1,056.40 | 528.20 |
| Mounjaro 7.5 mg | 1,468.64 | 734.32 |
| Mounjaro 10 mg | 1,468.64 | 734.32 |
| Mounjaro 12.5 mg | 1,987.84 | 993.92 |
| Mounjaro 15 mg | 1,987.43 | 993.72 |
| Foundayo 0.8 or 2.5 mg | 691.59 | No discount (691.59) |
| Foundayo 5.5 or 9 mg | 972.08 | No discount (972.08) |
| Foundayo 14.5 or 17.2 mg | 1,146.46 | No discount (1,146.46) |
| Wegovy pill 1.5 or 4 mg | 760.74 | No discount (760.74) |
| Wegovy pill 9 mg | 1,069.28 | No discount (1,069.28) |
| Wegovy pill 25 mg | 1,261.10 | No discount (1,261.10) |
Injection prices are taken from the Maccabi price list, and pill prices from the supplier’s price list. At Clalit, the Mounjaro price with supplementary insurance is slightly different, as noted above.
Who qualifies for a discount?
All four Israeli health funds now sell weight loss injections at a 50% discount through their supplementary insurance plans. The discount applies only to the injections; there is currently no discount on the pills. It is available to adults with a BMI over 30, or a BMI over 27 plus an obesity-related condition. These conditions include, for example, diabetes, high blood pressure, high blood lipids, fatty liver or sleep apnea.
To get the discount, you need to go through a set process at your health fund:
- Weight and height measured by a health fund nurse, to calculate your BMI.
- Taking part in a follow-up program with nutritional care, such as sessions with a dietitian.
- A prescription from a health fund doctor, in line with the criteria.
I explain the process step by step in my article on getting a prescription. You can also find a comparison between the health funds in my article on Mounjaro in Israel.
What about the national health basket?
In February 2026, the basket committee approved Wegovy injections for the first time, but only for teens aged 12 to 18. However, adults were left out, mainly because of the high cost. That is why adults still pay out of pocket, with or without a discount. You can read the full background in my article on weight loss drugs and the health basket. Full list prices for each drug are also updated from time to time in the Israeli Ministry of Health drug price database.
How to plan your spending
Before you start treatment, it helps to do some simple math. First, check whether you have supplementary insurance and whether you meet the criteria. Second, remember that prices rise with the dose, so your budget for the first year will be higher than your first month’s cost. In addition, ask your doctor which dose is right for you in the long run. After all, not every patient needs the highest dose to succeed.
Why weight loss drug prices can decide whether treatment works
Obesity is a chronic disease, and treating it takes continuity over time. When a patient stops an effective treatment because of cost, the risk of regaining weight and losing the metabolic gains goes up. In addition, trust in the medical system suffers. A US study of about 125,000 patients found that 64.8% of patients without diabetes stopped treatment within a year. Moreover, among patients with diabetes, higher income was linked to a lower rate of stopping. You can read about what happens after stopping in my article on coming off weight loss drugs.
In other words, the debate over weight loss drug prices is not only about money. It is a medical, public and social issue of the first order.
Looking ahead: will weight loss drug prices come down?
More drugs, including pills, are expected to enter the market and increase competition. For example, the Wegovy pill reached Israel in November 2026. Meanwhile, the World Health Organization issued a global guideline in December 2025 on using GLP-1 medicines to treat obesity. Specifically, the WHO noted their high cost and called for action to lower prices and widen access. Public and professional pressure in Israel is growing as well. The goal is to recognize obesity as a chronic disease in the health basket and to allow broad funding for effective treatment.
Until then, every patient should get professional, personalized medical advice. That advice should cover medication, nutrition, physical activity, emotional support and an understanding of the financial side. For guidance, dose adjustments and medical follow-up along the way, you are welcome to book a personal consultation with me.
The bottom line on weight loss drug prices
In 2026, a weight loss injection with supplementary insurance costs about 320 to roughly 1,000 NIS a month, depending on the drug and dose. The pills, however, cost the full price even through your health fund: Foundayo costs 691.59 to 1,146.46 NIS, and the Wegovy pill costs 760.74 to 1,261.10 NIS. Weight loss drug prices change from time to time, so check them with your health fund before you start. In the end, the right treatment is the one you can stay on over time. That is why financial planning is part of the medical plan itself.
The information in this article is general and does not replace personal medical advice.
References
Maccabi Healthcare Services: drug price list (Wegovy and Mounjaro)
Clalit joins the wave: Mounjaro sold at a discount (ynet, Hebrew)
The 2026 drug basket: free weight loss injections for teens only (ynet, Hebrew)
Drug prices – Israeli Ministry of Health (Hebrew)
No more injections? New weight-loss pill to launch in Israel next week
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
WHO issues global guideline on the use of GLP-1 medicines in treating obesity
